Date: {{$ActivityAssignDate}}

Dear Dr. {{$doctorName}},

Subject: Faropenem Observations & Review Study in the Management of Complicated Urinary Tract Infections (FOR Study)

Complicated urinary tract infections (cUTI) occur in individuals with functional or structural abnormalities of the genitourinary tract such as obstruction, neurological impairment, urological abnormalities/devices, immunological impairment, and congenital diseases. cUTI may be caused by a wide variety of organisms and many of them maybe resistant to broad-spectrum antimicrobial agents. Escherichia coli is the most common organism causing complicated UTI, but Citrobacter, Enterobacter, Pseudomonas, Staphylococcus aureus, and others are also seen in higher frequency (6%–20%) in complicated UTI as compared to uncomplicated UTI.

Patients of UTI may have myriad presentations varying from burning micturition and fever to severe sepsis and septic shock. It may also present as delirium or confusion in the elderly. The majority of UTIs are community acquired (57.4%), whereas 35.6% are health care associated and 7% are nosocomial.

There are multiple reports of antimicrobial resistance in the management of urinary tract infections. There is limited literature to support evidence-based recommendations for the management of this common medical condition. In India, an alternative to intravenous carbapenems is often prescribed by clinicians. Faropenem is an oral antibiotic that belongs to the “penems” class of β-lactam antibiotics. Faropenem has broad antimicrobial activity, is active against aerobic gram-positive, gram- negative, and anaerobic bacteria. In India, faropenem is approved for the treatment of respiratory tract, urinary tract, skin, soft-tissue, and gynecological infections.

There is limited Indian data on disease profile, management approach and usage of faropenem in complicated urinary tract infections. Hence this cross sectional study with Indian healthcare professionals will help to understand the disease profile, manageme nt and usage of faropenem in complicated urinary tract infections.

If you agree to participate, you will be required to respond to questionsof the enclosed questionnaire. We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.